Defunct Company
Total Trials
19
As Lead Sponsor
15
As Collaborator
4
Total Enrollment
4,653
NCT00867438
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2007
Completion: Nov 30, 2007
NCT03447821
Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea
Start: Feb 29, 2008
Completion: Jul 31, 2008
NCT00679380
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
Phase: Phase 3
Role: Collaborator
Start: Jun 30, 2008
Completion: Apr 30, 2010
NCT00968656
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Phase: Phase 1
Start: Jan 31, 2009
Completion: Nov 30, 2011
NCT01100112
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
Start: Feb 28, 2010
Completion: Aug 31, 2010
NCT01142089
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
Start: May 27, 2010
Completion: Jun 30, 2012
NCT03287219
Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Start: May 2, 2011
Completion: Jan 16, 2012
NCT01520324
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Start: Jan 31, 2012
Completion: Jul 31, 2012
NCT01520337
Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy
Phase: N/A
Completion: Oct 31, 2013
NCT01790386
Equivalency Study of the TEG and CORA Hemostasis Systems
Start: Jan 31, 2013
Completion: Dec 31, 2013
NCT02295774
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Start: Feb 28, 2013
Completion: Dec 31, 2014
NCT01694966
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Start: Sep 30, 2013
Completion: Oct 31, 2016
NCT02408029
Trauma Equivalency Study of the CORA® and TEG® 5000 Systems
Start: Mar 31, 2015
Completion: Oct 31, 2015
NCT02969252
Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers
Start: Jul 31, 2015
Completion: Not specified
NCT02654418
Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm
Start: Feb 29, 2016
Completion: Jul 31, 2017
NCT03099785
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
Start: Dec 18, 2017
Completion: Dec 14, 2020
NCT03863145
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Phase: Early Phase 1
Start: Jun 14, 2022
Completion: Jun 1, 2026
NCT06936332
Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne
Start: Nov 18, 2024
Completion: Apr 10, 2025
NCT06368648
CoMind Early Feasibility Study
Start: Nov 27, 2024
Completion: Oct 31, 2025